This site is intended for healthcare professionals
News

Bylvay is European Commission approved to treat progressive familial intrahepatic cholestasis.

Read time: 1 mins
Last updated:21st Jul 2021
Published:21st Jul 2021
Albireo Pharma, Inc. announced that the European Commission has approved its cholestasis drug, Bylvay (odevixibat) for treating progressive familial intrahepatic cholestasis (PFIC).The drug is the first and only once-daily drug approved for treating all subtypes of PFIC, globally. PFIC is a rare and devastating disorder affecting young children. The disease causes progressive, life-threatening liver disease, which may progress to cirrhosis and liver failure within the first 10 years of life.
Condition: Progressive Familial Intrahepatic Cholestasis
Type: drug
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest